Your browser doesn't support javascript.
loading
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Moreau, Philippe; Dimopoulos, Meletios-Athanasios; Mikhael, Joseph; Yong, Kwee; Capra, Marcelo; Facon, Thierry; Hajek, Roman; Spicka, Ivan; Baker, Ross; Kim, Kihyun; Martinez, Gracia; Min, Chang-Ki; Pour, Ludek; Leleu, Xavier; Oriol, Albert; Koh, Youngil; Suzuki, Kenshi; Risse, Marie-Laure; Asset, Gaelle; Macé, Sandrine; Martin, Thomas.
Afiliação
  • Moreau P; Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France. Electronic address: philippe.moreau@chu-nantes.fr.
  • Dimopoulos MA; The National and Kapodistrian University of Athens, Athens, Greece.
  • Mikhael J; Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA.
  • Yong K; Department of Haematology, University College Hospital, London, UK.
  • Capra M; Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil.
  • Facon T; Lille University Hospital, Lille, France.
  • Hajek R; Department of Hemato-Oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
  • Spicka I; 1st Department of Medicine-Department of Hematology, 1st Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic.
  • Baker R; Perth Blood Institute, Murdoch University, Perth, WA, Australia.
  • Kim K; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Martinez G; Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Sao Paolo, Brazil.
  • Min CK; Department of Hematology, Catholic Hematology Hospital and Leukemia Research Institute, Seoul, South Korea.
  • Pour L; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
  • Leleu X; Service d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402, Poitiers, France.
  • Oriol A; Institut Josep Carreras and Institut Catala d'Oncologia, Hospital Germans Trias I Pujol, Badalona, Spain.
  • Koh Y; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
  • Suzuki K; Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center, Tokyo, Japan.
  • Risse ML; Sanofi R&D, Vitry-sur-Seine, France.
  • Asset G; Sanofi R&D, Chilly-Mazarin, France.
  • Macé S; Sanofi R&D, Vitry-sur-Seine, France.
  • Martin T; Department of Hematology, University of California San Francisco, San Francisco, CA, USA.
Lancet ; 397(10292): 2361-2371, 2021 06 19.
Article em En | MEDLINE | ID: mdl-34097854
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article